Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Public ClinicalTrials.gov record NCT01632241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
Study identification
- NCT ID
- NCT01632241
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 503 participants
Conditions and interventions
Conditions
Interventions
- Placebo plus standard therapy Biological
- Belimumab 10 mg/kg plus standard therapy Biological
- Standard therapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2013 (Actual)
- Primary completion
- Jun 18, 2018 (Actual)
- Completion
- Jan 28, 2019 (Actual)
- Last update posted
- Sep 8, 2021
2013 – 2019
United States locations
- U.S. sites
- 64
- U.S. states
- 22
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35216 | — |
| GSK Investigational Site | Covina | California | 91723 | — |
| GSK Investigational Site | La Palma | California | 90623 | — |
| GSK Investigational Site | Lakewood | California | 90712 | — |
| GSK Investigational Site | Los Alamitos | California | 90720 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Murrieta | California | 92563 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Bridgeport | Connecticut | 06606 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20060 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | DeBary | Florida | 32713 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33334 | — |
| GSK Investigational Site | Longwood | Florida | 32750 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Miami | Florida | 33144 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | — |
| GSK Investigational Site | Orlando | Florida | 32804 | — |
| GSK Investigational Site | Orlando | Florida | 32806-6264 | — |
| GSK Investigational Site | Plantation | Florida | 33324 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Tampa | Florida | 33603 | — |
| GSK Investigational Site | Atlanta | Georgia | 30303 | — |
| GSK Investigational Site | Duluth | Georgia | 30096 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| GSK Investigational Site | Boston | Massachusetts | 02115 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | Lansing | Michigan | 48917 | — |
| GSK Investigational Site | Jackson | Mississippi | 39216 | — |
| GSK Investigational Site | St Louis | Missouri | 63110 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89102 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89128 | — |
| GSK Investigational Site | Clifton | New Jersey | 07012 | — |
| GSK Investigational Site | Brooklyn | New York | 11201 | — |
| GSK Investigational Site | Brooklyn | New York | 11203 | — |
| GSK Investigational Site | Brooklyn | New York | 11215 | — |
| GSK Investigational Site | Great Neck | New York | 11021 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28210 | — |
| GSK Investigational Site | Greenville | North Carolina | 27834 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27617 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Columbus | Ohio | 43203 | — |
| GSK Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| GSK Investigational Site | Charleston | South Carolina | 29425 | — |
| GSK Investigational Site | Columbia | South Carolina | 29204 | — |
| GSK Investigational Site | Columbia | South Carolina | 29229 | — |
| GSK Investigational Site | Jackson | Tennessee | 38305 | — |
| GSK Investigational Site | Memphis | Tennessee | 38119 | — |
| GSK Investigational Site | Memphis | Tennessee | 38163 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Austin | Texas | 78731 | — |
| GSK Investigational Site | Dallas | Texas | 75246 | — |
| GSK Investigational Site | Dallas | Texas | 75390-8550 | — |
| GSK Investigational Site | Houston | Texas | 77004 | — |
| GSK Investigational Site | Houston | Texas | 77034 | — |
| GSK Investigational Site | The Woodlands | Texas | 77382 | — |
| GSK Investigational Site | Arlington | Virginia | 22205-3606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01632241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2021 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01632241 live on ClinicalTrials.gov.